Đánh giá kết quả điều trị u máu thể Kassabach-Merritt qua 26 trường hợp

Kassabach Merritt Syndrome (KMS) is a rare vascular tumor characterized by enlarging vascular lesion, thrombocytopenia, and serious coagulation disorders. Haigouni Kassabach and Katherine Krom Merrit are the two pediatricians who first described the disease in 1940. There is no consensus in definitive treatment for KMS world-wide yet. Its mortality rate is about 13-30 percent. The combination of Intralesional Bleomycin Injection and Propranolol in treating KMS a provides a new opportunity for cure with many advantages that need further research attentions. Research objectives: To study diagnostic workup and treatment outcome of by using Bleomycin and Proparnolol. Research methodology: Case Report.